Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.74

€0.74

-2.880%
-0.022
-2.880%
€5.07

€5.07

 
24.05.24 / Tradegate WKN: A2N4RX / Symbol: GRTS / Name: Gritstone Oncology / Stock / Pharmaceuticals / Small Cap /
Latest predictions
€2.76
24.05.24
0.00%
buy
€3.70
13.05.24
-1.33%
buy
02.04.24
-41.96%
02.04.24
-51.16%
€6.43
06.03.24
-62.28%
buy
€6.63
28.09.23
-47.96%
buy
Your prediction

Gritstone Oncology Inc Stock

We can see a decrease in the price for Gritstone Oncology Inc. Compared to yesterday it has lost -€0.022 (-2.880%).
Currently there is a rather positive sentiment for Gritstone Oncology Inc with 4 Buy predictions and 2 Sell predictions.
Based on the current price of 0.74 € the target price of 5 € shows a potential of 575.68% for Gritstone Oncology Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Gritstone Oncology Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Market Position" there were negative voices in the community.

Pros and Cons of Gritstone Oncology Inc in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gritstone Oncology Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Gritstone Oncology Inc -2.880% 7.558% -3.141% -54.657% -60.172% -89.952% -
Rockwell Medical Inc. 0.240% 2.310% 18.169% -29.957% -5.479% -79.363% -96.462%
Avid Bioservices Inc -2.990% -2.994% 28.571% -40.441% 32.787% -50.610% 148.924%
Pacira Pharmaceuticals -1.430% -1.429% 15.966% -25.806% -7.383% -48.411% -28.172%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-09

Nur wenige Unternehmen können den Sturm, der sich in der pharmazeutischen Branche abspielt, überleben. Auf der einen Seite stehen die immensen Kosten für Forschung und Entwicklung und auf der anderen Seite der Druck nach mehr bezahlbaren Medikamenten. Für einige Unternehmen, wie Gritstone Oncology (Börsensymbol GRTS), scheint allerdings dieses Szenario eine Gelegenheit zu bieten.

Gritstone Oncology steht finanziell betrachtet vor großen Herausforderungen. Da das Unternehmen noch in der Entwicklungsphase steckt, hat es nur begrenzte Einnahmen aus Produktverkäufen. Gleichzeitig sind die Ausgaben für Forschung und Entwicklung (F&E) – mit Ausgaben von 111,4 Millionen USD, 97,5 Millionen USD und 88,6 Millionen USD in den Jahren 2022, 2021 und 2020 – beträchtlich.

Ein positiver Aspekt der finanziellen Lage von Gritstone Oncology ist die solide Bilanz. Das Unternehmen verfügte zum 31. Dezember 2022 über Vermögenswerte in Höhe von 240,75 Millionen USD und ein Eigenkapital von 170,78 Millionen USD. Das bedeutet, dass das Unternehmen über ausreichende Ressourcen verfügt, um seine laufenden Aktivitäten zu finanzieren.

Comments

Prediction Buy
Perf. (%) 0.00%
Target price 2.765
Change
Ends at 24.05.25

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $3.00 price target on the stock, down previously from $6.00.
Ratings data for GRTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.33%
Target price 3.704
Change
Ends at 13.05.25

Gritstone bio, Inc. (NASDAQ: GRTS) had its price target lowered by analysts at HC Wainwright from $7.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for GRTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -62.28%
Target price 6.430
Change
Ends at 06.03.25

Gritstone bio, Inc. (NASDAQ: GRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Ratings data for GRTS provided by MarketBeat
Show more